Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Dimebon in Huntington's disease
2007-003293-25Phase 2Completed
- Sponsor
- Medivation
- Start
- Jul 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing Dimebon with Placebo (2 arms). Primary endpoint: Completion of 90-day dosing period on assigned study medication. Started Jul 2007; status: completed.
02
Drugs
latrepirdine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2007-003293-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003293-25.